Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive treatment

J Am Acad Dermatol. 2020 Jul;83(1):285-287. doi: 10.1016/j.jaad.2020.04.085. Epub 2020 Apr 21.

Authors

Paolo Gisondi¹, Gianluigi Zaza², Micol Del Giglio³, Mattia Rossi², Valentina Iacono², Giampiero Girolomoni³

Affiliations

¹ Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy. Electronic address: paolo.gisondi@univr.it.
² Section of Nephrology, Department of Medicine, University of Verona, Verona, Italy.
³ Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.

No abstract available

Publication types

Observational Study

MeSH terms

Adult
Aged
Betacoronavirus / immunology*
Betacoronavirus / isolation & purification
Biological Products / adverse effects
COVID-19
Coronavirus Infections / immunology
Coronavirus Infections / mortality*
Coronavirus Infections / therapy
Coronavirus Infections / virology
Dermatologic Agents / adverse effects
Electronic Health Records / statistics & numerical data
Female
Hospitalization / statistics & numerical data*
Hospitals, University / statistics & numerical data
Humans
Immunosuppressive Agents / adverse effects*
Italy / epidemiology
Kidney Transplantation / adverse effects
Male
Middle Aged
Pandemics
Pneumonia, Viral / immunology
Pneumonia, Viral / mortality*
Pneumonia, Viral / therapy
Pneumonia, Viral / virology
Psoriasis / drug therapy*
Psoriasis / immunology
Psoriasis / mortality
Retrospective Studies
Risk Assessment
SARS-CoV-2
Transplant Recipients / statistics & numerical data*

Substances

Biological Products
Dermatologic Agents
Immunosuppressive Agents